This site is intended only for healthcare professionals resident in India

Search

Menu

Close

Sign InLog Out
Our medicinesTherapy areasExplore ContentExplore contentMaterialsVideosLet's connectLet's ConnectPfizer medical information

Menu

Close

AboutUnmet NeedCommunity-acquired PneumoniaComplicated Skin & Soft Tissue InfectionsMode of ActionVideoCommunity-acquired PneumoniaComplicated Skin & Soft Tissue InfectionsPatient ProfilesProfiles of Patients With CAPIdentify ZINFORO® Patient With CAPProfiles of Patients With cSSTIIdentify ZINFORO® Patient With cSSTIDosingRecommended Dosing ScheduleSimple DosingRenal AdjustmentEfficacyCommunity-acquired PneumoniaClinical Efficacy: Proven Clinical EfficacyClinical Efficacy: Evidence of Rapid ResponsePivotal Clinical StudiesMicrobiology: Optimising OutcomesMicrobiology: CoverageMicrobiology: Low MIC ValuesComplicated Skin & Soft Tissue InfectionsClinical Efficacy: Proven Clinical EfficacyClinical Efficacy: Evidence of Rapid ResponsePivotal Clinical StudiesMicrobiology: Optimising OutcomesMicrobiology: CoverageMicrobiology: Low MIC ValuesSafetySafetyKey safety featuresLow Incidence of Discontinuation in CAPLow Incidence of Discontinuation in cSSTIClinical & Scientific Data Clinical & Scientific Data Efficacy in the Treatment of CAPClinical Cure Rates Against Relevant PathogensClinical Cure Rates Across Patient SubgroupsDemonstrated Superiority to CeftriaxoneEarly Clinical ResponseReal-world Efficacy in Elderly PatientsConsistent Clinical Cure Rates in cSSTIClinical Cure Rates in Common Causative PathogensClinical Cure Rates in Patients With ComorbiditiesEarly Clinical EfficacyReal-life Efficacy in Clinical PracticeSupport & ResourcesSupport & ResourcesClinical updatesPrescribing InformationVideosWebinarsExplore Materials


Profiles of Patients With CAP

ZINFORO® (ceftaroline fosamil): Profiles of patients with CAP

Identifying a patient with CAP who may benefit from ZINFORO®
In patients with CAP, initial antimicrobial treatment modification occurs in >25% of patients and is frequently the result of insufficient response or treatment failure.1,*

   

George, a 70-year-old nursing home resident, presents with fever, cough and sputum production.

Severity
  • PORT Score IV (severe)
  • 70-year-old male
  • RR >30 breaths/minute
  • Temperature >40°C
  • Nursing home resident
History/Comorbidities
  • Structural lung disease
  • History of smoking
Risk factors for difficult-to-treat infection
  • Age >65 years
  • Recurrent infection (hospitalised for pneumonia 3 months ago)
 
Marco presents with fever, cough and pleuritic chest pain and there has been no improvement with ceftriaxone.

Severity
  • PORT Score IV (severe)
  • 78-year-old male
  • Chronic renal disease
  • Pulse >125 bpm
  • RR >30 breaths/minute
  • No clinical improvement within 72 hours of ceftriaxone initiation
History/Comorbidities
  • Renal insufficiency
  • Recent alcoholism
Risk factors for difficult-to-treat infection
  • Age >65 years
  • Medical comorbidities
  • Alcoholism
 
Marie presents with fever, dyspnoea and cough.                                                                              

Severity
  • PORT Score III (moderate)
  • 56-year-old female
  • PO2 <90% (upon admission)
  • Glucose >250
  • Increasing oxygen requirements to maintain oxygen saturation
  • May require ICU in the next 24 hours
History/Comorbidities
  • Asthma
  • Diabetes
Risk factors for difficult-to-treat infection
  • Recent antibiotic exposure for URTI within previous 3 months

Severity
  • PORT Score IV (severe)
  • 78-year-old male
  • Chronic renal disease
  • Pulse >125 bpm
  • RR >30 breaths/minute
  • No clinical improvement within 72 hours of ceftriaxone initiation
History/Comorbidities
  • Renal insufficiency
  • Recent alcoholism
Risk factors for difficult-to-treat infection
  • Age >65 years
  • Medical comorbidities
  • Alcoholism
 



​​​​​Please note: The examples described here are not of actual patients, but fictitious representations of scenarios for which ZINFORO® (ceftaroline fosamil) could be considered.

Refer to the local product document for further information on ZINFORO®.2

*There is no experience with ZINFORO® (ceftaroline fosamil) in the treatment of CAP in the following patient groups: The immunocompromised, patients with severe sepsis/septic shock and severe underlying lung disease, patients with PORT risk Class V, and/or CAP requiring ventilation at presentation, CAP due to MRSA and patients requiring intensive care; the available clinical data cannot substantiate efficacy against PNSP.2

bpm, beats per minute; cSSTI, complicated skin and soft tissue infection; CAP, community-acquired pneumonia; ICU, intensive care unit; MRSA, methicillin-resistant Staphylococcus aureus; PNSP, penicillin-nonsusceptible pneumococci; PO2, partial pressure of oxygen; PORT, Pneumonia Patient Outcomes Research Team; RR, respiratory rate; URTI, upper respiratory tract infection.


References:

Blasi F, Garau J, Medina J, et al. Current management of patients hospitalized with community-acquired pneumonia across Europe: outcomes from REACH. Respir Res. 2013;14(1):44.Zinforo. Local product document. Pfizer; 2021. Version LPDZIN072021.


​​​​​Please click the Prescribing Information link to view the safety and adverse events information of ZINFORO®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
​​​​​​​
PP-ZFO-IND-0417 June 2022
Patient Profiles​​​​​​​

Example

Dosing

Simple dosing with a flexible infusion time

Learn moreLoading


Efficacy

Proven clinical efficacy in patients with
CAP and cSSTI

 Review efficacy profile


Safety

Safety profile consistent with other cephalosporins

 Review safety profile


Clinical & Scientific Data

​​​​ZINFORO® in the treatment of CAP and cSSTI​​​​​​

 Learn more
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out
 
These pages are not intended for patients or for members of the general public. The web pages contain promotional content. For the use only of Registered Medical Practitioners or a Hospital or a Laboratory. Full prescribing information available on request. For more details on, Who is a Registered Medical Practitioner, please visit "https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf", Page No. 39, Rule 2 part (ee), last accessed on 26th April2021.
​​​​​​​
Address: The Capital,  A Wing, 1802, 18th Floor, Plot No. C-70, ‘G’ Block, Bandra Kurla Complex, Bandra East, Mumbai – 400051, India.
 
PP-ZFO-IND-0417

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

ButtonButton

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.

Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.

Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.

Copyright © 2023 Pfizer Limited, India. All rights reserved. Applicable for Pfizer Products, Product Microsites and Therapy Areas section of the website:
  • All content published herein is intended and strictly only for informational, educational, academic and/or research purposes and shall not be utilized to diagnose or treat a health problem or disease without referring to the full prescribing information for list of approved indications as contained in the product package insert
  • While due care and caution has been taken to ensure that the content herein is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information herein
For the use of Registered Medical Practitioners only*

These pages are not intended for patients or for members of the general public. The web pages contain promotional content.


If you select 'No', you will be redirected to Pfizer.co.in

For more details on, Who is a Registered Medical Practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
​​​​​​​Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.


PP-DOL-IND-0251 18 JAN 2023
Yes No
You are now leaving PfizerPro website
​
​​​​​You are now leaving Pfizer Pro website and will be redirected to another website. Note that you will be governed by the Terms & Conditions and Privacy Policy of the external website. Would you like to continue?
PP-DOL-IND-0251 18 JAN 2023